AU2005210085B2 - The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and COPD - Google Patents

The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and COPD Download PDF

Info

Publication number
AU2005210085B2
AU2005210085B2 AU2005210085A AU2005210085A AU2005210085B2 AU 2005210085 B2 AU2005210085 B2 AU 2005210085B2 AU 2005210085 A AU2005210085 A AU 2005210085A AU 2005210085 A AU2005210085 A AU 2005210085A AU 2005210085 B2 AU2005210085 B2 AU 2005210085B2
Authority
AU
Australia
Prior art keywords
glycopyrrolate
budesonide
day
copd
acceptable salts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005210085A
Other languages
English (en)
Other versions
AU2005210085A1 (en
Inventor
Peter Jurgen Cnota
Joachim Goede
Joachim Maus
Istvan Szelenyi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Meda Pharma GmbH and Co KG
Original Assignee
Meda Pharma GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meda Pharma GmbH and Co KG filed Critical Meda Pharma GmbH and Co KG
Publication of AU2005210085A1 publication Critical patent/AU2005210085A1/en
Application granted granted Critical
Publication of AU2005210085B2 publication Critical patent/AU2005210085B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2005210085A 2004-02-06 2005-01-24 The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and COPD Ceased AU2005210085B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54195604P 2004-02-06 2004-02-06
US60/541,956 2004-02-06
PCT/EP2005/000652 WO2005074918A1 (en) 2004-02-06 2005-01-24 The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and copd

Publications (2)

Publication Number Publication Date
AU2005210085A1 AU2005210085A1 (en) 2005-08-18
AU2005210085B2 true AU2005210085B2 (en) 2010-06-24

Family

ID=34837533

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005210085A Ceased AU2005210085B2 (en) 2004-02-06 2005-01-24 The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and COPD

Country Status (16)

Country Link
US (2) US20050175548A1 (enExample)
EP (1) EP1713473B1 (enExample)
JP (1) JP4819699B2 (enExample)
CN (1) CN100569235C (enExample)
AU (1) AU2005210085B2 (enExample)
CA (1) CA2551780C (enExample)
DK (1) DK1713473T3 (enExample)
ES (1) ES2413011T3 (enExample)
HR (1) HRP20130460T1 (enExample)
NO (1) NO336882B1 (enExample)
NZ (1) NZ548300A (enExample)
PL (1) PL1713473T3 (enExample)
PT (1) PT1713473E (enExample)
RU (1) RU2440813C2 (enExample)
SI (1) SI1713473T1 (enExample)
WO (1) WO2005074918A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
GB0523653D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523654D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523655D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523656D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
PL1971369T3 (pl) * 2005-12-21 2010-01-29 Meda Pharma Gmbh & Co Kg Połączenie R,R-glikopirolanu, rolipramu i budesonidu dla potrzeb leczenia chorób zapalnych
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
WO2009142589A1 (en) * 2008-05-20 2009-11-26 Astrazeneca Ab Combination of (a) glucocorticoid receptor modulator and (b) a muscarinic antagonist
PT2435025T (pt) * 2009-05-29 2016-11-11 Pearl Therapeutics Inc Administração, por via respiratória, de agentes activos
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
WO2011076841A2 (en) 2009-12-23 2011-06-30 Chiesi Farmaceutici S.P.A. Combination therapy for copd
HRP20140582T4 (hr) 2009-12-23 2023-06-09 Chiesi Farmaceutici S.P.A. Kombinacijska terapija za copd
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
CA2881182C (en) * 2012-08-09 2021-01-26 Chase Pharmaceuticals Corporation Piperidinium quaternary salts
NZ710740A (en) 2013-02-28 2020-06-26 Dermira Inc Glycopyrrolate salts
US8558008B2 (en) 2013-02-28 2013-10-15 Dermira, Inc. Crystalline glycopyrrolate tosylate
US9006462B2 (en) 2013-02-28 2015-04-14 Dermira, Inc. Glycopyrrolate salts
JP6454323B2 (ja) 2013-03-15 2019-01-16 パール セラピューティクス，インコーポレイテッド 粒子状結晶性材料のコンディショニングのための方法及びシステム
AU2014375301C1 (en) 2013-12-30 2026-02-19 Chiesi Farmaceutici S.P.A. Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination
WO2016149756A1 (en) * 2015-03-23 2016-09-29 The University Of Melbourne Treatment of respiratory diseases
US20160310410A1 (en) 2015-04-24 2016-10-27 Glenmark Specialty S.A. Pharmaceutical compositions comprising arformoterol and glycopyrronium
US10098837B2 (en) 2016-07-28 2018-10-16 Chiesi Farmaceutici S.P.A. Combination therapy for COPD
JP6781829B2 (ja) 2016-09-19 2020-11-04 メキシケム フロー エセ・ア・デ・セ・ヴェ 医薬組成物
RU2691110C2 (ru) * 2017-11-20 2019-06-11 Федеральное государственное бюджетное учреждение науки Сибирский федеральный научный центр агробиотехнологий Российской академии наук (СФНЦА РАН) Препарат для лечения заболеваний дыхательных путей у лошадей и способ его применения
AU2019374731B2 (en) 2018-11-07 2025-08-21 Tianli Biotech Pty Ltd Compounds and compositions for the treatment of respiratory diseases
CN109498625B (zh) * 2018-12-29 2021-04-16 温州医科大学附属第一医院 一种治疗慢性阻塞性肺疾病的药物组合物及其制备方法
PH12022551243A1 (en) 2019-12-02 2023-09-11 Chiesi Farm Spa Stainles steel can for pressurised metered dose inhalers
US12673065B2 (en) 2020-09-02 2026-07-07 Kuwait University Anti-inflammatory composition and method of treatment
CN120360953B (zh) * 2025-06-24 2025-09-05 成都第一制药有限公司 一种用于copd治疗的莨菪烷类生物碱组合物及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001076575A2 (en) * 2000-04-07 2001-10-18 Arakis Ltd. The treatment of respiratory diseases
US6475467B1 (en) * 1998-08-04 2002-11-05 Jago Research Ag Medicinal aerosol formulations
US6475466B1 (en) * 1999-03-19 2002-11-05 Micro Therapeutics, Inc. Methods for treating endoleaks during endovascular repair of abdominal aortic aneurysms
US20030223937A1 (en) * 2002-04-12 2003-12-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments comprising steroids and a novel anticholinergic

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ290266B6 (cs) 1993-07-02 2002-06-12 Byk Gulden Lomberg Chemische Fabrik Gmbh Substituované benzamidy, způsob jejich výroby a farmaceutické prostředky s jejich obsahem
EP0932401A1 (en) * 1996-07-01 1999-08-04 Sepracor, Inc. Methods and compositions for treating urinary incontinence using enantiomerically enriched (r,r)-glycopyrrolate
US6384038B1 (en) 1998-04-14 2002-05-07 Sepracor Inc. Methods and compositions using cetirizine in combination with leukotriene inhibitors or decongestants
US6402285B1 (en) 1998-05-29 2002-06-11 Citizen Watch Co., Ltd. Method of subjecting ink jet printer to preuse treatment
CN1150895C (zh) * 1998-11-13 2004-05-26 杰格研究股份公司 用于吸入给药的干粉
US6086914A (en) 1999-03-12 2000-07-11 Weinstein; Robert E. Nonsedating formulations for allergic rhinitis which possess antihistaminic and anticholinergic activity
DE19921693A1 (de) 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
US20040002548A1 (en) 1999-05-12 2004-01-01 Boehringer Ingelheim Pharma Kg Medicament compositions containing anticholinergically-effective compounds and betamimetics
DE19961300A1 (de) 1999-12-18 2001-06-21 Asta Medica Ag Vorratssystem für Arzneimittel in Pulverform und damit ausgestatteter Inhalator
DE10007203A1 (de) 2000-02-17 2001-08-23 Asta Medica Ag Neue Kombination nichtsedierender Antihistaminika mit Substanzen, die die Leukotrienwirkung beeinflussen, zur Behandlung der Rhinitis/Konjunktivitis
GB0009583D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory formulations
GB0009584D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Pharmaceutical compositions
DE10062712A1 (de) 2000-12-15 2002-06-20 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Corticosteroiden
DE10110772A1 (de) 2001-03-07 2002-09-12 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und PDE-IV-Inhibitoren
GB0029903D0 (en) * 2000-12-07 2001-01-24 Arakis Ltd Use of anti-muscarinic agents
CN100496608C (zh) * 2001-03-30 2009-06-10 洁垢技术有限公司 药用气溶胶制剂
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
WO2002096423A2 (en) 2001-05-25 2002-12-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Combination of a pde4 inhibitor and tiotropium or derivate thereof for treating obstructive airways
PA8546001A1 (es) 2001-05-25 2003-12-30 Pfizer Un inhibidor de pde4 y un agente anticolinergico en combinacion para tratar enfermedades obstructivas de vias respiratorias
GB0118373D0 (en) 2001-07-27 2001-09-19 Glaxo Group Ltd Novel therapeutic method
CN1422620A (zh) * 2001-12-07 2003-06-11 中国人民解放军总装备部后勤部军事医学研究所 治疗氮氧化物中毒的气雾剂及其用途和制备方法
US7258118B2 (en) * 2002-01-24 2007-08-21 Sofotec Gmbh & Co, Kg Pharmaceutical powder cartridge, and inhaler equipped with same
CA2478974C (en) * 2002-03-20 2014-12-16 Advanced Inhalation Research, Inc. Inhalable sustained therapeutic formulations
DE10216429A1 (de) * 2002-04-12 2003-10-23 Boehringer Ingelheim Pharma Arzneimittel enthaltend Steroide und ein neues Anticholinergikum
US20040038958A1 (en) 2002-07-11 2004-02-26 Chris Rundfeldt Topical treatment of skin diseases
UA82323C2 (uk) 2002-08-09 2008-04-10 Меда Фарма Гмбх & Ко. Кг Нова комбінація глюкокортикоїду та pde-інгібітору для лікування респіраторних захворювань, алергічних захворювань, астми та хронічних обструктивних легеневих захворювань
AU2003272450A1 (en) 2002-09-13 2004-04-30 C. Steven Smith Novel composition and method for treatment of upper respiratory conditions
EP1610788A1 (en) 2003-03-28 2006-01-04 ALTANA Pharma AG Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases
PT1610787E (pt) 2003-03-28 2008-04-23 Nycomed Gmbh Associação sinérgica compreendendo roflumilast e um agente anticolinérgico seleccionado de sais de tiotrópio para o tratamento de doenças respiratórias
US20060155491A1 (en) * 2003-07-11 2006-07-13 Peter Bode Frequency determination
CA2550841C (en) 2004-02-06 2012-10-02 Meda Pharma Gmbh & Co. Kg Novel combination of anticholinergic and .beta. mimetics for the treatment of respiratory diseases
JP2007524698A (ja) 2004-02-27 2007-08-30 アルタナ　ファルマ　アクチエンゲゼルシャフト シクレソニドとグリコピロニウムとの組合せ物
PL1971369T3 (pl) 2005-12-21 2010-01-29 Meda Pharma Gmbh & Co Kg Połączenie R,R-glikopirolanu, rolipramu i budesonidu dla potrzeb leczenia chorób zapalnych

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6475467B1 (en) * 1998-08-04 2002-11-05 Jago Research Ag Medicinal aerosol formulations
US6475466B1 (en) * 1999-03-19 2002-11-05 Micro Therapeutics, Inc. Methods for treating endoleaks during endovascular repair of abdominal aortic aneurysms
WO2001076575A2 (en) * 2000-04-07 2001-10-18 Arakis Ltd. The treatment of respiratory diseases
US20030223937A1 (en) * 2002-04-12 2003-12-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments comprising steroids and a novel anticholinergic

Also Published As

Publication number Publication date
DK1713473T3 (da) 2013-06-17
RU2440813C2 (ru) 2012-01-27
SI1713473T1 (sl) 2013-06-28
NO336882B1 (no) 2015-11-23
EP1713473A1 (en) 2006-10-25
RU2006132038A (ru) 2008-03-20
PL1713473T3 (pl) 2013-08-30
CA2551780C (en) 2013-02-26
WO2005074918A1 (en) 2005-08-18
AU2005210085A1 (en) 2005-08-18
HRP20130460T1 (hr) 2013-06-30
NO20063879L (no) 2006-11-01
CN100569235C (zh) 2009-12-16
PT1713473E (pt) 2013-05-13
US10537550B2 (en) 2020-01-21
CA2551780A1 (en) 2005-08-18
US20080300226A1 (en) 2008-12-04
EP1713473B1 (en) 2013-03-13
CN1913883A (zh) 2007-02-14
JP4819699B2 (ja) 2011-11-24
HK1098356A1 (zh) 2007-07-20
JP2007520508A (ja) 2007-07-26
ES2413011T3 (es) 2013-07-15
US20050175548A1 (en) 2005-08-11
NZ548300A (en) 2010-04-30

Similar Documents

Publication Publication Date Title
US10537550B2 (en) Methods of treating underlying inflammation from COPD or asthma
CA2632780C (en) Combination of r,r-glycopyrrolate, rolipram, and budesonide for the treatment of inflammatory diseases
JP6501774B2 (ja) Ｍａｂａ化合物およびコルチコステロイドを含む組合せ剤
JP2006519204A (ja) 高効能の持続性ベータ２−アゴニストを他の活性成分と組み合わせて含んでなる薬剤
AU2014222646A1 (en) Combinations comprising MABA compounds and corticosteroids
MX2007000424A (es) Combinaciones de estatinas con broncodilatadores.
AU2003292120B2 (en) New synergistic combination comprising roflumilast and formoterol
KR102448406B1 (ko) Ａｅｒｄ/천식에서 트롬복산 수용체 길항제
AU2003288169B8 (en) Synergistic combination comprising roflumilast and (R,R) -formoterol
MXPA06008938A (en) The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and copd
HK1098356B (en) The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and copd
JP5220741B2 (ja) アンドラスト／グルココルチコイドの併用
HK40066392A (en) Thromboxane receptor antagonists in aerd/asthma
WO2010071582A1 (en) Pharmaceutical product comprising a muscarinic receptor antagonist and a second active ingredient
JP2013056925A (ja) アンドラスト／グルココルチコイドの併用
HK1087009B (en) Medicament comprising a highly potent long-lasting beta2-agonist in combination with other active ingredients
HK1232788A1 (en) Combinations of tiotropium bromide, formoterol and budesonide for the treatment of copd

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired